These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964 [TBL] [Abstract][Full Text] [Related]
30. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114 [TBL] [Abstract][Full Text] [Related]
31. CBX4 suppresses CD8 Wang J; Jia W; Zhou X; Ma Z; Liu J; Lan P Theranostics; 2024; 14(10):3793-3809. PubMed ID: 38994031 [No Abstract] [Full Text] [Related]
32. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026 [TBL] [Abstract][Full Text] [Related]
34. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932 [TBL] [Abstract][Full Text] [Related]
35. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713 [TBL] [Abstract][Full Text] [Related]
36. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
38. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Jin W; Zhou XF; Yu J; Cheng X; Sun SC Blood; 2009 Jun; 113(26):6603-10. PubMed ID: 19411637 [TBL] [Abstract][Full Text] [Related]
39. A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8 Ma R; Ji T; Zhang H; Dong W; Chen X; Xu P; Chen D; Liang X; Yin X; Liu Y; Ma J; Tang K; Zhang Y; Peng Y; Lu J; Zhang Y; Qin X; Cao X; Wan Y; Huang B Nat Cell Biol; 2018 Jan; 20(1):21-27. PubMed ID: 29230018 [TBL] [Abstract][Full Text] [Related]
40. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]